Literature DB >> 6780914

Genetic basis of BCG-induced suppression of delayed hypersensitivity.

D J Schrier, J L Sternick, E M Allen, V L Moore.   

Abstract

BCG can either act as an adjuvant to potentiate immunological responses or, in some cases, can induce suppression. The reasons for these differential activities are not clear but may include routes and doses of administration, as well as variable host reactivity to the agent. In this study, we have used killed BCG administered intravenously to produce chronic granulomatous inflammation (CGI) in the lungs and spleen of inbred mice. We report that strains which develop CGI were usually anergic, as evaluated by the development of delayed hypersensitivity (DH) to sheep erythrocytes (SRBC). Studies on the genetics of BCG-induced anergy indicated that it was unigenic, recessive and linked (approximately 28 recombination units) to the immunoglobulin heavy-chain allotype (Igh). There was no influence by genes linked to the major histocompatibility complex. The study indicates that anergy associated with CGI is under genetic control, which may explain the variability of anergy in patients with granulomatous diseases. The implication of linkage to the Igh complex is not clear, but it may be associated with VH receptors on T lymphocytes, which in turn act on macrophages to mediate suppression.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6780914     DOI: 10.1038/289405a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  9 in total

Review 1.  Mouse chromosome 12.

Authors:  P D'Eustachio
Journal:  Mamm Genome       Date:  1992       Impact factor: 2.957

2.  Post-operative intrapleural BCG in lung cancer: a 5-year follow-up report.

Authors:  W Bakker; J M Nijhuis-Heddes; E A van der Velde
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

Review 3.  Genetic aspects of innate resistance and acquired immunity to mycobacteria in inbred mice.

Authors:  E Buschman; A S Apt; B V Nickonenko; A M Moroz; M H Averbakh; E Skamene
Journal:  Springer Semin Immunopathol       Date:  1988

4.  The immunologic and immunotherapeutic sequelae of intraperitoneal BCG. II: Serial changes in spleen weight, morphology, cell populations and in vitro mitogen responses.

Authors:  W R Roche; H McLaughlin
Journal:  Ir J Med Sci       Date:  1983-08       Impact factor: 1.568

5.  The immunologic and immunotherapeutic sequelae of intraperitoneal BCG. I: The local nature of immunostimulation and the effects of delayed-type hypersensitivity.

Authors:  W R Roche; H McLaughlin
Journal:  Ir J Med Sci       Date:  1983-08       Impact factor: 1.568

6.  Complementation of allotype- and nonallotype-linked genes in the induction of low-zone tolerance to phage fd.

Authors:  J Heuer; E Kölsch
Journal:  Immunogenetics       Date:  1981       Impact factor: 2.846

7.  Mycobacterium bovis, BCG, modulation of murine antibody responses: influence of dose and degree of aggregation of live or dead organisms.

Authors:  C A Brown; I N Brown
Journal:  Br J Exp Pathol       Date:  1982-04

8.  Influence of the Ity/Lsh/Bcg gene on the development of suppressor cell precursors in the early phase of the infection of mice with Mycobacterium lepraemurium.

Authors:  D Gosselin; R Turcotte; S Lemieux
Journal:  Clin Exp Immunol       Date:  1994-05       Impact factor: 4.330

9.  Immunogenetics of BCG-induced anergy in mice. Control by Igh- and H-2-linked genes.

Authors:  A H Callis; D J Schrier; C S David; V L Moore
Journal:  Immunology       Date:  1983-08       Impact factor: 7.397

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.